JP5795693B2 - 晶癖を有する結晶及び該結晶を有効成分として含有する医薬組成物 - Google Patents

晶癖を有する結晶及び該結晶を有効成分として含有する医薬組成物 Download PDF

Info

Publication number
JP5795693B2
JP5795693B2 JP2015000723A JP2015000723A JP5795693B2 JP 5795693 B2 JP5795693 B2 JP 5795693B2 JP 2015000723 A JP2015000723 A JP 2015000723A JP 2015000723 A JP2015000723 A JP 2015000723A JP 5795693 B2 JP5795693 B2 JP 5795693B2
Authority
JP
Japan
Prior art keywords
crystal
plane
luliconazole
pharmaceutical composition
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015000723A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015063566A5 (enExample
JP2015063566A (ja
Inventor
孝明 増田
孝明 増田
後藤　誠
誠 後藤
秀夫 金田
秀夫 金田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pola Pharma Inc
Nihon Nohyaku Co Ltd
Original Assignee
Pola Pharma Inc
Nihon Nohyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pola Pharma Inc, Nihon Nohyaku Co Ltd filed Critical Pola Pharma Inc
Priority to JP2015000723A priority Critical patent/JP5795693B2/ja
Publication of JP2015063566A publication Critical patent/JP2015063566A/ja
Publication of JP2015063566A5 publication Critical patent/JP2015063566A5/ja
Application granted granted Critical
Publication of JP5795693B2 publication Critical patent/JP5795693B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Landscapes

  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
JP2015000723A 2015-01-06 2015-01-06 晶癖を有する結晶及び該結晶を有効成分として含有する医薬組成物 Active JP5795693B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2015000723A JP5795693B2 (ja) 2015-01-06 2015-01-06 晶癖を有する結晶及び該結晶を有効成分として含有する医薬組成物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2015000723A JP5795693B2 (ja) 2015-01-06 2015-01-06 晶癖を有する結晶及び該結晶を有効成分として含有する医薬組成物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2013185313A Division JP5680161B1 (ja) 2013-09-06 2013-09-06 晶癖を有する結晶及び該結晶を有効成分として含有する医薬組成物

Publications (3)

Publication Number Publication Date
JP2015063566A JP2015063566A (ja) 2015-04-09
JP2015063566A5 JP2015063566A5 (enExample) 2015-05-21
JP5795693B2 true JP5795693B2 (ja) 2015-10-14

Family

ID=52831740

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015000723A Active JP5795693B2 (ja) 2015-01-06 2015-01-06 晶癖を有する結晶及び該結晶を有効成分として含有する医薬組成物

Country Status (1)

Country Link
JP (1) JP5795693B2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6480228B2 (ja) 2015-03-26 2019-03-06 日本碍子株式会社 ガスセンサ
JP2017101009A (ja) 2015-12-04 2017-06-08 株式会社ポーラファルマ 抗アカントアメーバ剤及びその製造法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3278738B2 (ja) * 1995-07-08 2002-04-30 日本農薬株式会社 抗真菌剤
KR20100075475A (ko) * 2007-09-05 2010-07-02 가부시키가이샤 폴라 파마 의약 조성물
CN103012385B (zh) * 2012-02-17 2015-07-08 山东威智医药工业有限公司 卢立康唑的晶型及其制备方法

Also Published As

Publication number Publication date
JP2015063566A (ja) 2015-04-09

Similar Documents

Publication Publication Date Title
JP2021105030A (ja) ニコチンアミドリボシドの結晶形
TWI856415B (zh) (s)-2-乙基丁基2-(((s)-(((2r,3s,4r,5r)-5-(4-胺基吡咯并[2,1-f] [1,2,4]三嗪-7-基)-5-氰基-3,4-二羥基四氫呋喃-2-基)甲氧基)(苯氧基)磷醯基)胺基)丙酸酯之結晶形式
JP5589130B1 (ja) 結晶及び該結晶を含有してなる医薬製剤
EP2964641B1 (en) Crystalline form having specific crystal habit and pharmaceutical composition containing this crystalline form as active ingredient
EP3174891A2 (en) Crystalline form of nicotinamide riboside
WO2020219524A1 (en) A 7h-pyrrolo[2,3-d]pyrimidine jak-inhibitor
EP3279201B1 (en) Cdk inhibitor, eutectic crystal of mek inhibitor, and preparation method therefor
JP6126040B2 (ja) ニコサミド（Ｎｉｃｏｕｓａｍｉｄｅ）化合物の五つの晶型、その製法やその薬物組合と用途
TWI496773B (zh) Ｎ－［２－［［（２，３－二氟苯基）甲基］硫基］－６－｛［（１ｒ，２ｓ）－２，３－二羥基－１－甲基丙基］氧基｝－４－嘧啶基］－１－三亞甲亞胺磺醯胺之新穎結晶型
JP5680161B1 (ja) 晶癖を有する結晶及び該結晶を有効成分として含有する医薬組成物
JP5795693B2 (ja) 晶癖を有する結晶及び該結晶を有効成分として含有する医薬組成物
AU2016269359B2 (en) Sodium salt of uric acid transporter inhibitor and crystalline form thereof
EA020455B1 (ru) Бис(дигидрофосфатная) соль 6-{2-[1-(6-метил-3-пиридазинил)-4-пиперидинил]этокси}-3-этокси-1,2-бензизоксазола (1:2), способ ее получения и ее применение в композиции и способе лечения или предотвращения пикорнавирусных инфекций
US20080234323A1 (en) Amorphous and Three Crystalline Forms of Rimonabant Hydrochloride
JP5698395B2 (ja) 結晶及び該結晶を含有してなる医薬製剤
CA3196518A1 (fr) Analogues du 5 alpha-hydroxy-6 beta-[2-(1-h-imidazol-4-yl)ethylamino]-cholestan-3 beta-ol et compositions pharmaceutiques le comprenant pour utilisation dans le traitement du cancer
CN118512427A (zh) 四氢姜黄素在制备治疗膀胱癌的药物中的用途
CN103040808B (zh) 苯基丙酸取代四氢吡喃酮用于制备抗真菌感染药物的用途
CN103040811B (zh) 对甲氧基苯氨基吡喃酮用于制备抗真菌感染药物的用途
HK1247726B (zh) 烟酰胺核苷的结晶形式
CN103788044A (zh) 硝克柳胺化合物晶i型、其制法和其药物组合物与用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150316

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150316

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20150316

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20150402

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150512

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150728

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150813

R150 Certificate of patent or registration of utility model

Ref document number: 5795693

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

R371 Transfer withdrawn

Free format text: JAPANESE INTERMEDIATE CODE: R371

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313115

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250